-+ 0.00%
-+ 0.00%
-+ 0.00%
Eikon Therapeutics Receives FDA Clearance To Proceed For Investigational New Drug Application To Evaluate EIK1006 For Treatment Of Advanced Metastatic Prostate Cancer; Expects Initial Clinical Data From Phase 1/2 Study In H2 2027
Share
Listen to the news

Eikon plans to initiate a Phase 1/2 study, ARGATE-001, to evaluate the safety, tolerability and preliminary efficacy of EIK1006 in participants with metastatic androgen-pathway-modulation-resistant prostate cancer (mAPMRPC) that has progressed on established anti-hormonal therapy. Formerly known as metastatic castration-resistant prostate cancer (mCRPC), mAPMRPC remains an area of high unmet need because resistance to established anti-hormonal therapy is common and limits durable benefit. EIK1006 is intended to address resistance driven by androgen receptor (AR) pathway alterations, including AR amplification and ligand-binding domain mutations. Eikon expects to begin dosing participants in this study in 2027, with preliminary safety and efficacy data to be available in the second half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending